Trial Profile
An open-label evaluation of the safety and efficacy of a combination of niacin ER [extended-release] and simvastatin in patients with dyslipidaemia (OCEANS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 May 2008
Price :
$35
*
At a glance
- Drugs Niacin/simvastatin (Primary)
- Indications Lipid metabolism disorders
- Focus Adverse reactions; Registrational
- Acronyms OCEANS
- 08 Aug 2006 Status change
- 10 Oct 2005 New trial record.